Why is Sublocade (buprenorphine) preferred over monthly Brixadi (buprenorphine/naloxone sublingual film) for a patient who needs a long‑acting injectable and has difficulty with sublingual administration?

Why Not Brixadi Monthly Instead of Sublocade?

Both Brixadi (monthly) and Sublocade are appropriate long-acting injectable buprenorphine formulations for opioid use disorder, and there is no strong evidence-based reason to categorically prefer one over the other—the choice should be guided by dosing flexibility needs, patient-specific pharmacokinetics, and clinical context.

Key Differences Between the Two Formulations

Dosing Flexibility

• Brixadi offers multiple dose strengths (64 mg, 96 mg, 128 mg, and 160 mg monthly formulations), allowing more granular dose adjustments 1
• Sublocade provides only two fixed monthly doses: 300 mg (initial) and 100 mg (maintenance), with limited flexibility 2

Brixadi's multiple dosing options may be advantageous when patients require intermediate doses or when tapering, as it allows stepwise dose reductions rather than the binary choice between 300 mg and 100 mg 3, 1.

Initiation Protocols

• Brixadi can be used for both treatment initiation (in opioid-dependent patients) and for switching from sublingual buprenorphine 1
• Sublocade requires patients to be stabilized on transmucosal buprenorphine before the first injection—specifically, patients must demonstrate tolerance to sublingual buprenorphine prior to administration 2

This distinction is clinically meaningful: if a patient has difficulty with sublingual administration (as your question implies), Brixadi may offer a pathway to initiate injectable treatment more directly, though both products ultimately require some demonstration of buprenorphine tolerance to avoid precipitated withdrawal 2.

Pharmacokinetic Considerations

Plasma Concentration Profiles

Both formulations use biodegradable polymer depot technology, but their release kinetics differ:

• Sublocade demonstrates accumulation over the first 2 months with the 100 mg maintenance dose, with further accumulation at the 300 mg dose reaching steady-state after the fourth monthly injection 2
• Brixadi pharmacokinetics show more predictable weekly or monthly release patterns with multiple dosing options 1

Delayed Withdrawal Risk

A critical safety consideration: both formulations can cause delayed withdrawal symptoms months after the last dose due to prolonged buprenorphine release from the depot 3. One case report documented withdrawal symptoms 4 months after a single 200 mg Sublocade dose, with naltrexone challenge confirming ongoing μ-opioid receptor agonism 3. This risk applies to both products and necessitates:

• Extended monitoring for 6-12 months after discontinuation
• Explicit informed consent about delayed withdrawal
• Availability of rescue strategies (transdermal buprenorphine, clonidine, gabapentin, or return to maintenance) 3

Clinical Outcomes and Safety

Treatment Retention and Healthcare Utilization

Real-world evidence demonstrates:

• 67% one-year retention rate on LAI buprenorphine (primarily Brixadi in Swedish cohorts), with 89% overall OAT continuation when including transitions to sublingual forms 4
• 50% reduction in inpatient care days (from 9.0 to 4.5 days) after switching to LAI buprenorphine, translating to approximately $4,090 USD cost savings per patient 4
• Among patients remaining on LAI at 12 months, inpatient days decreased even more dramatically (74% reduction) 4

Adverse Events

Both formulations share similar adverse event profiles inherent to buprenorphine:

• QTc prolongation (≤15 msec), though unlikely to be pro-arrhythmic when used alone 2
• Respiratory depression risk, particularly with concomitant CNS depressants 2
• Hepatotoxicity concerns in patients with moderate-to-severe hepatic impairment 2
• Encephalopathy has been reported with Brixadi in at least one case (128 mg monthly dose causing altered mental status) 5

Patients with pre-existing moderate-to-severe hepatic impairment are not candidates for Sublocade because dose adjustments cannot be rapidly made due to the long-acting depot 2. Similar caution likely applies to Brixadi.

Special Populations and Clinical Scenarios

Perioperative Management

Guidelines recommend continuing buprenorphine (including long-acting formulations like Sublocade) perioperatively in most cases 6, 7. The 2019 PAIN consensus statement indicates:

• It is almost always appropriate to continue buprenorphine at the preoperative dose (Level 5 evidence) 7
• Multimodal analgesia and regional techniques should be prioritized
• Higher-than-normal doses of full opioid agonists may be required for acute pain due to buprenorphine's high μ-opioid receptor affinity 8, 7

This guidance applies equally to both Sublocade and Brixadi, though the inability to rapidly adjust LAI doses means acute pain management requires careful planning with non-opioid analgesics and potentially high-affinity full agonists (fentanyl, hydromorphone) under close supervision 2.

Pregnancy and Lactation

Both products contain buprenorphine, which is compatible with breastfeeding (relative infant dose <1% of maternal dose) 2. However, chronic opioid use may reduce fertility in both sexes, and this effect's reversibility is unknown 2.

Patient Selection

Retrospective cohort data suggest patients transitioning to LAI buprenorphine (primarily Brixadi in Australian settings) were more likely to have:

• Comorbid mental illness
• Longer duration of unsanctioned opioid use
• Untreated hepatitis C infection
• Single relationship status 9

This suggests LAI formulations may be preferentially used in patients with higher psychosocial complexity to facilitate treatment engagement 9.

Practical Decision-Making Algorithm

Choose Brixadi when:

• Dose flexibility is needed (intermediate doses, tapering plans)
• Patient may benefit from direct initiation onto LAI (though still requires opioid dependence confirmation)
• Stepwise dose adjustments are anticipated

Choose Sublocade when:

• Patient is already stable on sublingual buprenorphine 8-24 mg daily
• Simple two-dose regimen (300 mg → 100 mg) is adequate
• Longer track record in U.S. market is preferred (approved earlier than Brixadi)

Both formulations are contraindicated when:

• Moderate-to-severe hepatic impairment exists (cannot rapidly adjust depot levels) 2
• Patient is opioid-naïve (risk of fatal respiratory depression) 2
• Hypersensitivity to buprenorphine is documented 2

Common Pitfalls to Avoid

1. Do not assume LAI formulations eliminate the need for psychosocial support—comprehensive addiction treatment requires behavioral interventions alongside pharmacotherapy 10

2. Do not initiate LAI buprenorphine without confirming opioid dependence—precipitated withdrawal can occur if administered too soon after full agonist opioids (wait ≥6 hours for short-acting, ≥24 hours for long-acting opioids) 2

3. Do not underestimate delayed withdrawal risk—monitor patients for 6-12 months after discontinuation and have rescue protocols ready 3

4. Do not forget depot removal may be necessary if moderate-to-severe hepatic impairment develops during treatment or if toxicity/overdose occurs within 2 weeks of administration 2

5. Do not use LAI formulations as first-line for acute pain management—these are maintenance treatments for OUD, not analgesics 11

The evidence does not support a categorical preference for Sublocade over Brixadi monthly. The decision should be individualized based on dosing needs, initiation context, and patient-specific factors, with both formulations offering effective, safe options for long-term OUD treatment when appropriately selected and monitored.